1,125
Views
14
CrossRef citations to date
0
Altmetric
Editorial

Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?

, DVM PhD (Professor)

Bibliography

  • Chambon P, Weill J, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963;11:39-43
  • Hottiger MO. Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics. Annu Rev Biochem 2015;84:227-63
  • Hottiger MO, Hassa PO, Luscher B, et al. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010;35(4):208-19
  • Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. OncoTargets and therapy 2015;8:519-28
  • Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30(3):283-8
  • Sonnenblick A, de Azambuja E, Azim HAJr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12(1):27-41
  • Editor’s Summary. Cancer therapy: stop PARP. 2005. Available from: http://www.nature.com/nature/journal/v434/n7035/edsumm/e050414-12.html
  • Pirinen E, Canto C, Jo YS, et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;19(6):1034-41
  • Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12(9):852-61
  • Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19(11):1381-8
  • De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013;3:228
  • Giansanti V, Dona F, Tillhon M, Scovassi AI. PARP inhibitors: new tools to protect from inflammation. Biochem Pharmacol 2010;80(12):1869-77
  • Garcia-Parra J, Dalmases A, Morancho B, et al. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. Eur J Cancer 2014;50(15):2725-34
  • Toller IM, Altmeyer M, Kohler E, et al. Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia. Cancer Res 2010;70(14):5912-22
  • Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012;11(12):923-36

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.